Trial reportDrug design, development and therapy2025
Application of Loading Dose Warfarin in Postpartum Women with Pulmonary Embolism - a Prospective, Randomized, Double-Blind Trial.
Trial report in Drug design, development and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Warfarin is usually used in a fixed loading dose regimen, which may increase the risk of bleeding or prolong the time to reach standard dose. The aim of the study is to compare the efficacy and safety of loading dose versus maintenance dose of warfarin therapy in postpartum women with pulmonary embolism (PE) under the guidance of clinical pharmacogenetic information. Patients and Methods: A total of 64 postpartum women with PE were recruited from September 2022 to August 2023. Participants were randomly divided 1:1 into two groups using a random-number table patients in the experimental group received a regimen combining the initial 1 to 3 days loading dose with the International Warfarin Pharmacogenetics Consortium (IWPC) model. Patients in the control group only received a regimen guided by the IWPC model for the initial 1 to 3 days. Starting from day 4, the warfarin dose was adjusted according to the international normalized ratio (INR). The primary outcome was first time to therapeutic INR (2.0-3.0). Results: The study found that the median time to first reach the therapeutic INR was 5.5 days in the experimental group compared to 7 days in the control group (p=0.002). The median time within therapeutic range (TTR) was 97.24% in the experimental group compared to 95.50% in the control group (p=0.001). The difference in adverse events showed no statistical significance between the two groups (P > 0.05). Conclusion: The study could provide ideas for the precise treatment of warfarin in postpartum women with PE. The integration of warfarin loading doses guided by pharmacogenetics into clinical practice can enhance decision-making, optimize patient outcomes, and reduce adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.